Cell-based reporter assays are transforming biologics development by providing sensitive, quantitative measurements of pathway activation in intact cells across discovery and clinical validation. For developers and tech professionals, these luciferase-based systems offer high-throughput compatibility and human-cell backgrounds that improve physiological relevance while streamlining workflows through optimized media and clonal consistency. This approach reduces regulatory risk and ensures lot-to-lot comparability, allowing for more precise mechanistic validation and reliable potency testing in immunotherapy and metabolic research.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
